CEMKA (France)

What CEMKA (France) does

CEMKA is a French consulting firm founded in 1989 and headquartered in Bourg-la-Reine, France, specializing in health economics, pharmaco-epidemiology, real-world evidence (RWE), market access, public health evaluation, and biostatistics. The company serves pharmaceutical and biotechnology companies (including Sanofi, Pfizer, Novartis, Roche, GSK, AstraZeneca, Bristol Myers Squibb, AbbVie, and Amgen), French public health authorities (CNAM, HAS, INSERM, INCA, OFDT), and patient organizations, delivering approximately 250 projects annually through a team of around 40 multi-disciplinary consultants.

The company's core technical capability is the exploitation of the French National Health Data System (SNDS), which covers 67 million subjects and includes PMSI, claims, and registry data, enabling construction of large-scale incident cohorts for chronic disease studies and health technology assessment. CEMKA has invested in applied AI and machine learning, notably through a CIFRE doctoral thesis with INRIA Team HeKa on rare disease trajectory analysis and event-order-aware predictive modeling, as well as NLP work presented at scientific conferences. The Asteria platform, accessible at asteriacemka.fr, provides query access to OpenData databases on drug and medical device usage, and is updated annually. CEMKA also operates the Cemkafé educational webinar series to engage the French health evaluation community.

CEMKA operates a professional services business model, generating revenue through project-based consulting fees priced according to scope, complexity, and timeline, with multi-year contracts common. Go-to-market is sales-led via direct B2B engagement with pharmaceutical, biotechnology, public health, and patient organization clients, supplemented by conference presence at AFCROs DSVR, ISPOR, EMOIS, and SantExpo, and thought leadership through peer-reviewed publications (over 50 articles). The company maintains GDPR compliance, operates as a French SAS (Société par Actions Simplifiée), and is independently owned with no disclosed institutional investors or parent company.

Name

CEMKA (France)

Legal name

CEMKA

Website

https://cemka.fr

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

11–50 employees

Short description

CEMKA is a French health consulting firm specializing in pharmaco-epidemiology, health economics, real-world evidence, market access, and public health evaluation. It serves pharmaceutical companies, French health authorities, and patient organizations with approximately 40 consultants delivering around 250 projects annually using SNDS data analytics.

Ownership category

akta.pro rank

Product category

Healthcare Consulting

NAICS

Management Consulting Services (54161), Other Scientific and Technical Consulting Services (54169), Other Management Consulting Services (541618)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

akta.pro secondary industry

Regulatory Operations & Publishing (eCTD, RIM, Submission Management) (HLAGAKAC)

Keywords

• Health economics consulting
• Pharmacoepidemiology studies
• Real-world evidence generation
• Market access services
• Public health evaluation

Headquarters

HQ city

Bourg-la-reine

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Consulting Services: Project-based consulting fees for pharmaceutical companies, biotech firms, and public institutions requiring epidemiological studies, health economics evaluations, market access strategies, and public health analyses.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

CEMKA is a French consulting firm providing expertise in pharmaco-epidemiology, health economics (HEOR), real-world evidence, market access and pricing, public health evaluation, and biostatistics. Its services are delivered by approximately 40 multi-disciplinary consultants (physicians, pharmacists, economists, epidemiologists, biostatisticians) to pharmaceutical companies, biotechnology firms, and French public health institutions. The firm also operates the Asteria platform for accessing OpenData databases on drug and medical device usage in France.

Product overview

CEMKA is a specialized health consulting company offering a comprehensive portfolio of services rather than a single software product. The core offerings include pharmaco-epidemiology, health economics (HEOR), real-world evidence (RWE) studies, public health evaluations, and market access consulting. The company operates the Asteria platform for OpenData queries and conducts approximately 250 projects annually for pharmaceutical companies, biotechnology firms, and public health institutions (HAS, CNAM, Regional Health Agencies). Services are delivered by approximately 40 consultants including physicians, pharmacists, economists, epidemiologists, and biostatisticians, with expertise spanning database analyses using French national health data systems (SNDS, PMSI), clinical trials support, and health technology assessment.

Differentiator

Problem solved

Functional benefit

Brands

• Asteria: Platform for accessing drug and medical device usage reports, accessible at https://www.asteriacemka.fr/login/
• Cemkafé

Products and services

• Pharmaco-Epidémiologie Services Pharmaco-epidemiological studies and surveys analyzing drug utilization patterns and safety profiles using real-world data sources, delivered to pharmaceutical companies and public health institutions.
• Economie de la Santé Services Health economics evaluations including cost-effectiveness analyses, budget impact models, and economic burden assessments for healthcare interventions, for pharmaceutical and biotech clients.
• Biométrie et Analyses de bases de données/SNDS Biometry and database analysis services utilizing the French National Health Data System (SNDS) for epidemiological research and real-world evidence generation, covering approximately 67 million subjects.
• Market Access & Pricing Services Market access strategy, pricing negotiations, and reimbursement dossier preparation for pharmaceuticals, vaccines, and medical devices including digital medical devices (DMN).
• Santé Publique Services Public health studies, health policy evaluations, and population health assessments including Article 51 experimentations evaluation for CNAM.
• Dispositifs médicaux numériques (DMN) et innovations Digital medical device evaluation and innovation assessment services for market access and regulatory compliance.
• Recueil de données et monitoring Clinical data collection, monitoring services, and real-world study implementation support.
• Revue de la littérature Systematic and non-systematic literature reviews, evidence synthesis, and structured economic literature reviews for health technology assessment.
• Direction médicale Services Medical direction and scientific advisory services for clinical development and medical affairs support.
• Asteria Platform Web-based platform for querying OpenData databases on drug and medical device usage in France, providing access to usage reports and statistics, updated annually.
• Real World Evidence (RWE) Services Design and implementation of observatories, registries, and database analyses for real-world evidence generation, including cohort studies such as SFDT1 for Type 1 diabetes.

Quantifiable outcome

• Evaluation of PRADO Maternité program showed reduced re-hospitalizations and costs for 648,823 mother-child dyades
• +2 more outcomes

Named customers22 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• MoiPatientcoreStrategic or Co-development Partner · 1 July 2026Ongoing collaboration on patient-centered research including 'Vieillir avec le VIH' (Aging with HIV) study with 14 patient associations.
• Cerballiance Laboratory NetworkcoreStrategic or Co-development Partner · 1 January 2026Collaboration for chronic kidney disease epidemiology study using biological data from Cerballiance laboratory network covering French territory.
• INRIA (Institut National de Recherche en Informatique et Automatique) - Team HeKacoreStrategic or Co-development Partner · 1 April 2024CIFRE thesis collaboration on AI methods for identifying care sequences specific to rare diseases, aiming to reduce diagnostic wandering using SNDS data. Collaboration with Pr. Anne-Sophie Jannot.
• CNAM (Caisse Nationale d'Assurance Maladie)coreStrategic or Co-development Partner · 1 February 2024Framework agreement renewed for evaluation of Article 51 health experiments. CEMKA serves as evaluator for innovative healthcare pathway experiments under the French healthcare reform framework.
• SNITEMminorStrategic or Co-development Partner · 1 January 2024Participation in SNITEM innovative startup events for medical devices, supporting digital medical device and innovation projects.
• ADES (Association des Étudiants du Master Évaluation)minorStrategic or Co-development Partner · 1 January 2022Partnership for student recruitment and industry networking. ADES is the association of students from the Evaluation Master's program.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• ICON plc: Large global CRO with a growing HEOR/RWE and market access practice, competing for the same pharmaceutical budgets as CEMKA across Europe.
• Syneos Health: Biopharmaceutical services organization offering integrated clinical and commercial services, including HEOR and market access consulting that overlap with CEMKA's offerings.
• IQVIA: Global CRO and healthcare data analytics leader offering HEOR, RWE, and market access services that directly overlap with CEMKA's pharmaco-epidemiology and SNDS-equivalent analytics offerings in France.
• Parexel International: Global CRO with significant HEOR, market access, and real-world evidence capabilities that compete with CEMKA's service portfolio for pharma clients.
• BearingPoint: European management and technology consultancy with healthcare and public-sector practices that bid on similar CNAM/HAS evaluations and pharma market access projects.

Direct peers

• Amaris Consulting (Mantu): International consulting group with French health economics and life sciences consulting capabilities, overlapping with CEMKA's pharma market access work.
• NEXTEP: French health economics and market access consultancy with a similar service portfolio (HEOR, RWE, market access) and similar pharma/public-sector client base in France.
• Stève Consultants: French health economics, pharmaco-epidemiology, and market access consulting firm — historically one of CEMKA's closest French competitors serving similar pharma and HAS clients.
• HEVA (now part of Putnam PHMR): French HEOR and market access consultancy offering health economics and real-world evidence services to pharma clients across France and Europe.

Emerging players

• Avia-GIS / SCRI (HEOR niche): Smaller French health economics and outcomes research consultancies serving the same pharma market access and reimbursement dossier market in France.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cemka-france-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CEMKA (France)